Metastatic Lung Cancer – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry


Empower your strategies with our Metastatic Lung Cancer – Drugs In Development, 2024 report and make more profitable business decisions.

Metastatic lung cancer, also known as stage IV lung cancer, is an advanced form of lung cancer characterized by the spread of cancerous cells from the lungs to distant parts of the body. It typically occurs when cancer cells break away from the primary tumor in the lungs and travel through the bloodstream or lymphatic system to other organs or tissues, forming secondary tumors. The two primary types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Both types can metastasize, but the most common type that spreads beyond the lungs is NSCLC.

The Metastatic Lung Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Metastatic Lung Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Lung Cancer and features dormant and discontinued products.


* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Metastatic Lung Cancer
Key Targets
· Epidermal Growth Factor Receptor ERB1; Cytotoxic T Lymphocyte Protein 4; DNA Topoisomerase II; 5' Nucleotidase; Adenosine Receptor A2b; Midkine; Nucleolin; Poly [ADP Ribose] Polymerase 2; Programmed Cell Death 1 Ligand 1; and Glycogen Synthase Kinase 3 Beta
Key Mechanisms of Action
· DNA Topoisomerase II Inhibitor; Cytotoxic T Lymphocyte Protein 4 Antagonist; Adenosine Receptor A2b Antagonist; Epidermal Growth Factor Receptor ERB1 Inhibitor; Midkine Inhibitor; Methionine Aminopeptidase 2 Inhibitor; MAP Kinase Activated Protein Kinase 2 Inhibitor; Interleukin 15 Activator; Interleukin 12 Activator; and Integrin Alpha 5 Antagonist
Key Routes of Administration
· Intravenous; Oral; Intratumor; Inhalational; Parenteral; Subcutaneous; Intraperitoneal; Intralesional; and Topical
Key Molecule Types
· Small Molecule; Monoclonal Antibody; Oncolytic Virus; Fusion Protein; Antisense RNAi Oligonucleotide; Antisense Oligonucleotide; Gene Therapy; Gene-Modified Cell Therapy; Recombinant Protein; and Synthetic Peptide
Major Companies
· Polyplus-Transfection SA; Portage Biotech Inc; Roquefort Therapeutics Plc; Genemedicine Ltd; Convalife; Bristol-Myers Squibb Co; BrYet US Inc; Cancer Targeting Systems Inc; CTx Operations Inc; and DeoBioSciences Inc


  • Therapeutics in Development: Covering 55 molecules, with 47 developed by companies and the rest by universities/institutes.
  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
  • Development History: Access the complete research and development history.
  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Metastatic Lung Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
  • Pipeline Exploration: Explore the detailed Metastatic Lung Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Metastatic Lung Cancer treatments for adaptable decision-making.
  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

ABM Therapeutics Inc
Accurius Therapeutics Inc
AntiCancer Inc
Arjuna Therapeutics
Arrogene Inc
Ascentawits Pharmaceuticals Ltd
AstraZeneca Plc
Beijing FuKangren Bio-pharm Tech Co Ltd
Bristol-Myers Squibb Co
BrYet US Inc
Cancer Targeting Systems Inc
CiMaas BV
Compass Therapeutics Inc
CTx Operations Inc
DeoBioSciences Inc
Enfuego Therapeutics Inc
For-Robin Inc
Genemedicine Ltd
Harry Perkins Institute of Medical Research
Hiroshima University
Hokkaido University
Huabo Biopharm (Shanghai) Co Ltd
Immupharma Plc
Institute of Cancer Research
Isarna Therapeutics GmbH
Kadmon Holdings Inc
Kintara Therapeutics Inc
Kintor Pharmaceutical Ltd
LeadArtis SL
MetaStat Inc
Moleculin Biotech Inc
National Cancer Institute US
Nob Hill Therapeutics Inc
Park of Active Molecules
PIN Pharma Inc
Polyplus-Transfection SA
Portage Biotech Inc
Princeton University
Provectus Biopharmaceuticals Inc
QSAM Therapeutics Inc
Replimune Ltd
Roquefort Therapeutics Plc
SL Bigen Co Ltd
SynDevRx Inc
University of California Riverside
University of Strathclyde
Vaxil Bio Therapeutics Ltd
ViruCure Therapeutics Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures


Global Markets Direct Report Coverage


Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones




Secondary Research

Primary Research

Expert Panel Validation

Contact Us



List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024


List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Metastatic Lung Cancer – Drugs In Development, 2024 in real time.

  • Access a live Metastatic Lung Cancer – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.